US Stocks Move | HUTCHMED (HCM.US) surges over 14%, reaches a licensing agreement with GlaxoSmithKline on cancer drug

智通财经APP reports that on Thursday, HUTCHMED (HCM.US) soared by more than 14%, closing at $13.75. In the news, HUTCHMED announced that its subsidiary, Hutchison Whampoa Pharmaceuticals (Shanghai), has entered into an exclusive development and licensing agreement with a subsidiary of GlaxoSmithKline (GSK.US), granting GSK’s subsidiary the global rights (except for Mainland China, Hong Kong, Macau, and Taiwan) to develop and commercialize HMPL-A830. Clinical development will initially focus on indications for colorectal cancer, pancreatic cancer, and lung cancer.